Canopy Growth Is Restating Two Years of Financials Before June 15 Earnings -- Here's What CGC Investors Need to Know Right Now

Canopy Growth announced it will restate financial results for two years due to a technical accounting error involving share-settled warrants that should have been classified as liabilities rather than equity. The company states the restatement won't impact revenue, operating income, cash flows, or key performance metrics. However, the stock remains a risky penny stock in a struggling marijuana sector facing intense competition and illicit market pressures. Most investors should avoid the stock until it achieves sustainable profitability and the restatement is complete.

05/22/2026, 11:15 PM • The Motley Fool

From $500 to $1: Is Canopy Growth a Dead Stock Walking or the Ultimate Turnaround Play?

Canopy Growth has lost 99.6% of its value over five years due to persistent profitability challenges, inability to enter the U.S. market directly, heavy cash burn, and shareholder dilution. While the stock could experience a dead cat bounce, long-standing issues and political gridlock limiting federal marijuana legalization make further downside possible. The article recommends financially stronger cannabis alternatives like Green Thumb Industries and Cronos Group, or marijuana ETFs, as better investment choices.

04/22/2026, 6:10 AM • The Motley Fool

The Major Long-Term Risk Facing Altria Stock in 2026

Altria faces a critical long-term challenge as its core cigarette business continues to decline with domestic shipments falling 10% in 2025. While the company has maintained profit growth through price increases, this strategy is unsustainable as smoking rates decline, particularly among young Americans. Although Altria's On! oral nicotine pouches show promise with 11% shipment growth, they face intense competition from Philip Morris's Zyn and lost market share in Q4. The company's diversification efforts have largely failed, and without successful next-generation products, Altria's stock faces eventual decline.

03/31/2026, 1:30 AM • The Motley Fool

Recreational Cannabis Market Report 2026-2035: A $3.32 Billion Market by 2030 - AI-Enabled Product Innovation, Novel Cannabis Beverages and Experience-Based Offerings Reshape Premiumization

The recreational cannabis market is projected to grow from $2.24 billion in 2025 to $3.32 billion by 2030, with a CAGR of 7.8-8.2%. Growth is driven by increasing legalization, public acceptance, demand for high-THC products, and innovation in premium edibles, beverages, and vape formats. Key players are launching innovative products and pursuing strategic acquisitions to capitalize on expanding market opportunities.

02/20/2026, 5:59 AM • GlobeNewswire

Format Innovation Reshapes a $438B Functional Market

The global functional food and beverage market is projected to reach $438 billion in 2026, with oral pouches and alternative caffeine delivery formats driving growth. Doseology Sciences launched caffeine-based energy pouches under its Feed That Brain brand, while Kraft Heinz introduced the HEINZ KegChup, Tilray Brands expanded spirits distribution in Illinois, Cronos Group launched Lord Jones cannabis in Israel, and USANA Health Sciences reported strong 2025 sales with positive 2026 guidance.

02/13/2026, 10:50 AM • Benzinga

Cronos Group Launches Premium Lord Jones® Brand in Israel, Advancing Borderless Product Strategy

Cronos Group Inc. announced the launch of its Lord Jones premium cannabis brand in Israel, marking a significant expansion of its borderless product strategy. The initial launch includes five premium indoor-grown flower strains available in Israeli pharmacies, with plans for future special edition and limited-run products. The move reflects Cronos' commitment to international growth and building globally recognized cannabis brands.

02/02/2026, 2:30 PM • GlobeNewswire

Cronos Group משיקה את מותג הפרימיום Lord Jones® בישראל ומקדמת אסטרטגיית מוצרים גלובלית חוצת גבולות

Cronos Group Inc. announced the launch of its premium Lord Jones cannabis brand in Israel, marking a significant milestone in its cross-border product strategy. The initial launch includes five premium flower strains grown under controlled indoor cultivation, targeting medical cannabis patients in Israel. The expansion reflects Cronos's commitment to responsible international growth and brand excellence.

02/02/2026, 2:30 PM • GlobeNewswire

Altria Group: Is This High-Yield Dividend Stock Too Cheap to Ignore?​

Altria Group faces declining revenues despite its traditional strategy of raising prices to offset falling smoking rates. While the stock trades at an attractive P/E ratio of 12 with a 6.8% dividend yield, the company's failed investments in e-cigarettes (Juul, NJOY) and cannabis (Cronos Group) have cost billions. With dividend payments consuming most of its free cash flow, the company risks its ability to sustain dividend growth unless it reverses revenue declines.

01/23/2026, 8:30 PM • The Motley Fool

High Hopes: Pot Stocks Blaze As Trump Eyes Rescheduling

President Trump is considering rescheduling marijuana from Schedule I to Schedule III, which could potentially remove tax burdens on cannabis businesses and improve their financial prospects.

12/17/2025, 11:26 AM • Benzinga

Cronos to enter the Netherlands with acquisition of Europe's largest adult-use cannabis company

Cronos Group is acquiring CanAdelaar, the largest cannabis company in the Netherlands' adult-use cannabis pilot program, for $67 million upfront, with potential additional earnouts. The acquisition provides Cronos strategic entry into the European cannabis market and establishes a market leadership position.

12/09/2025, 7:30 AM • Benzinga

Could Buying Altria Today Set You Up for Life?

Altria offers a high 6.4% dividend yield, but faces significant challenges including declining cigarette volumes, unsuccessful diversification attempts, and strategic missteps that could threaten its long-term dividend sustainability.

10/09/2025, 4:14 AM • The Motley Fool

1 Major Reason Cannabis Stocks Surged This Week

Marijuana stocks experienced significant gains after Donald Trump's video promoting hemp-derived CBD benefits and potential marijuana reclassification, with several cannabis companies and ETFs seeing notable price increases.

10/01/2025, 12:20 PM • The Motley Fool

President Trump Lights Up Cannabis Stocks With Pro-CBD Truth Social Post

President Trump posted a video on Truth Social promoting CBD's potential health benefits, suggesting Medicare coverage and potential healthcare system integration. This sparked a significant rally in cannabis stocks, with multiple companies seeing substantial price increases.

09/29/2025, 10:36 AM • Benzinga

What Is Trump Media Group CRO Strategy? And Should Investors Get on Board?

Trump Media announced plans to create a new Cronos treasury company, investing up to $6.4 billion in CRO tokens, which has recently seen a 90% price surge. Despite the short-term excitement, the long-term prospects of the cryptocurrency remain uncertain.

09/06/2025, 5:15 AM • The Motley Fool

UPDATE -- Valour Launches Eight New ETPs on Spotlight Stock Market, Including Shiba Inu (SHIB), Pi (PI), Ondo (ONDO), Cronos (CRO), Mantle (MNT), VeChain (VET), Ethena (ENA), and Celestia (TIA)

Valour Inc. has launched eight new SEK-denominated Exchange Traded Products (ETPs) on Sweden's Spotlight Stock Market, covering various digital assets like Shiba Inu, Pi, Ondo, and others, expanding its Nordic digital asset investment offerings.

08/27/2025, 11:17 PM • GlobeNewswire